Alexion Pharmaceuticals, Inc. Blog | Talkmarkets | Page 1
No data available
No data available
Latest Posts
1 to 16 of 89 Posts
1 2 3 ... 6
Healthcare And Biotechs Feel The Heat As The Market At New Highs
Article By: Tarun Chandra, CFA Wednesday, May 1, 2019 12:14 PM EDT
The stock market has continued to edge higher and the two major indexes, the Nasdaq (QQQ) and S&P 500 (SPY​), touched the all-time high milestone last week.
In this article: ACAD, ALXN, ARRY, AMRN, ARWR, AXSM, ASND
Read
5 Rallying Stocks For A Strong Q4
Article By: TipRanks Thursday, October 4, 2018 12:14 PM EDT
All these stocks are up over 10% or more in the last month.
In this article: CXO, CI, ALXN, BA, NTES
Read
Biotech ETFs In Focus On String Of Q2 Earnings Beats
Article By: Zacks Investment Research Sunday, August 12, 2018 4:27 PM EDT
The biotech sector has been performing remarkably well driven by a wave of mergers and acquisitions, new tax legislation, and a positive regulatory backdrop. Strong Q2 earnings results have added to the strength as biotech giants topped estimates.
In this article: IBB, AMGN, GILD, BBH, FBT, ALXN, BIIB
Read
Scan And Plan For Today’s Range And The Future Breakout
Video By: TheoTrade Thursday, May 24, 2018 5:01 PM EDT
Stocks sold off this morning on the news that President Trump canceled the meeting with North Korea. However, stocks recouped most of the loses by the close. In tonight's video newsletter we look at stocks that are break out candidates.
In this video: ALXN, USB, AMT, COO, DGX, HRB, CMG, PM
Watch
2018 Biotech Sector Watch On Earnings: ABBV, ALXN, BMY
Article By: Rod Raynovich Thursday, April 26, 2018 6:00 PM EDT
Abbvie (ABBV) is back on track. Alexion (ALXN) stock soared 14.6%. Bristol Myers-Squibb (BMY) raised its full year earnings forecast.
In this article: BMY, ALXN, ABBV Also: IBB, CELG, XBI, EDIT, CRSP
Read
Goldman Sachs: These 5 Stocks Can Break Higher
Article By: TipRanks Sunday, April 22, 2018 12:29 PM EDT
With the market in gridlock, Goldman Sachs has identified 14 stocks that seem to offer big upside potential.
In this article: NBL, NFX, ALXN, INCY, AVGO
Read
Alexion To Acquire Sweden's Wilson Therapeutics For $855M In Cash
Article By: The Fly Wednesday, April 11, 2018 8:05 AM EDT
Alexion Pharmaceuticals and Wilson Therapeutics AB announced that Alexion has made a recommended public cash offer to the shareholders in Wilson Therapeutics to acquire all outstanding shares in Wilson Therapeutics by way of a tender offer.
In this article: ALXN
Read
Alexion Jumps After Blood Disorder Drug Succeeds In Head-To-Head Trial
Article By: The Fly Thursday, March 15, 2018 8:36 AM EDT
Shares of Alexion jumped in pre-market trading after the company said its rare blood disorder drug was successful in a late-stage study.
In this article: ALXN
Read
5 Top Stocks To Survive A Trade War
Article By: TipRanks Sunday, March 4, 2018 5:58 PM EDT
President Trump has just announced that the US is about to impose 25% tariffs on steel imports and 10% on aluminium imports. But for Fundstrat founder and head of research Tom Lee the market is overreacting.
In this article: BA, PXD, RTN, ALXN, VRTX
Read
EC 2018 Outlook – Biotech Bonanza: Biotech Stocks To Keep Shining
Article By: Tarun Chandra, CFA Sunday, December 17, 2017 11:58 AM EDT
Biotech is not an easy sector to invest in - 95 percent of the oncology drugs that enter clinical trials fail. But that is no reason to ignore biotechs. We believe biotech stocks in 2018 will deliver double-digit returns of around 20%.
In this article: ALNY, ALXN, ABEO Also: ASH, ARNA, AMGN, BIIB, ANAB, SPPI, ZGNX, NKTR, EXAS, SAGE, HALO, SGMO, DVAX, INSM, XBI, JUNO, ESPR, LOXO, RVNC, LABD, LABU, BPMC, MRTX, NVS, CLLS, BLUE, BMY, INCY, CELG, GILD, VRTX, REGN
Read
Goldman Thinks It’s Time You ‘Sharpe’n Up
Article By: The Heisenberg Report Saturday, December 16, 2017 3:30 PM EDT
You damn sure can’t try to be a hero by betting against this self-fulfilling prophecy because that’s a one-way ticket to underperformance in a world where change has become impossible.
In this article: RRC, TAP, WDC, XRX, ALXN, DISH
Read
Biotech: Opportunity Ahead!
Article By: Tarun Chandra, CFA Thursday, November 30, 2017 2:18 PM EDT
December can prove to be a month of opportunity. We believe the passage of tax cuts this year can be the catalyst that jolts the biotech sector, to recover back the recent declines and even make new 52-week highs.
In this article: ALNY, ALXN, ABEO
Read
3 ETFs To Watch On Biotech Earnings
Article By: Zacks Investment Research Sunday, October 29, 2017 5:13 PM EDT
The earnings season is off to a flying start with equity markets. However, the performance has been a mixed bag for biotech companies with some beating market expectations, while a few failed to do so.
In this article: ALXN, AMGN, BIIB, BIB, IBB, BBH, GILD
Read
3 Biotech And Pharma Stocks With Key FDA Catalysts This October
Article By: Arpita Dutt Monday, October 2, 2017 10:16 AM EDT
The FDA, which approved 22 novel drugs last year, has given its approval to 34 drugs so far in 2017 including three in September.
In this article: FLXN, ALXN, PTCT Also: JNJ, TSRO, ACRX, AERI
Read
Here Are 5 Robust Stocks That Can Weather A Downturn
Article By: TipRanks Sunday, October 1, 2017 9:57 AM EDT
Payment processing giant Mastercard is one of the strongest payment companies out there. As the world increasingly moves away from cash and towards digital payments, MA stands to reap the rewards.
In this article: MA, ALXN, CELG, IDXX, BABA
Read
Alexion: Canada's Drug Price Watchdog Ordered Price Cut For Soliris
Article By: Shock Exchange Saturday, September 30, 2017 7:55 PM EDT
Canada's drug price watchdog ordered ALXN to cut prices for Soliris. A potential revenue slow down in the second half of 2017 implies growth is dead. Price cuts in Canada could hasten ALXN's slow down and cause negative sentiment for the stock.
In this article: ALXN
Read
1 to 16 of 89 Posts
1 2 3 ... 6